Journal of Translational and Practical Medicine regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Case Report
A hemodialysis case with fungemia due to Candida parapsilosis after COVID-19 infection
Bacterial and fungal infections may emerge with or following COVID-19 infection. Corticosteroids, antibiotics, and other therapies utilized in severe cases of COVID-19 pneumonia may pose a risk for fungal infections. In this paper, we present the case of a 59-year-old female patient with underlying chronic renal failure and diabetes who received long-term corticosteroid therapy for COVID-19 pneumonia and subsequently developed fungemia and catheter infection due to Candida parapsilosis. We removed her subclavian catheter and administered amphotericin -B therapy for 37 days. Overall, we recommend keeping in mind that opportunistic fungal infections may emerge in patients receiving long-term immunosuppressive drug therapy due to COVID-19 with risk factors such as hemodialysis, central venous catheter use, and broad-spectrum antibiotic use.

1. Calvo GS, Araújo GRS, Pastor EL, et al. Candida spp. co-infectionin COVID-19 patients with severe pneumonia: Prevalencestudy and associated risk factors. Respir Med. 2021;188:106619.doi:10.1016/j.rmed.2021.106619.
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinicalcharacteristics of 99 cases of 2019 novel Coronavirus pneumoniain Wuhan, China:a descriptive study. Lancet. 2020;395:507-513.doi:10.1016/S0140-6736(20)30211-7.
3. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the“Cytokine Storm” in COVID-19. J Infect. 2020;80:607-613.doi:10.1016/j.jinf.2020.03.037.
4. Zuo XS Liu Y, Cai X, Zhan L, Hu K. Association of differentCandida species with catheter-related candidemia, andthe potential antifungal treatments against their adhesionproperties and biofilm-forming capabilities. J Clin Lab Anal.2021;35(4):e23738. doi:10.1002/jcla.23738
5. Yamin DH, Husin A, Harun A. Risk factors of Candidaparapsilosis catheter-related bloodstream infection. Front PublicHealth. 2021;9:631865. doi.org/10.3389/fpubh.2021.631865.
6. Kayaaslan B, Kalem AK, Asilturk D, et al. Incidence and riskfactors for COVID-19 associated candidemia (CAC) in ICUpatients. Mycoses. 2022;65(5):508-516.
7. Liu F, Zhong L, Zhou F, et al. Clinical features, strain distribution,antifungal resistance and prognosis of patients with non-albicanscandidemia: a retrospective observational study. Infect DrugResist. 2021;14:3233-3246.
8. Coşkun AS, Durmaz ŞÖ. Fungal infections in COVID-19intensive care patients. Pol J Microbiol. 2021;70(3):395-400.
9. Zhang J, Lan P, Yi J, et al. Secondary bloodstream infectionin critically ill patients with COVID-19. J Int Med Res. 2021;49(12):3000605211062783. doi:10.1177/03000605211062783.
10. Martínez AR, Pascual IP, Guinea J, et al. Impact of the COVID-19pandemic on the clinical profile of candidemia and the incidenceof fungemia due to fluconazole-resistant Candida parapsilosis. JFungi (Basel) 2022;8(5):451. doi:10.3390/jof8050451.
Volume 2, Issue 1, 2023
Page : 26-29